Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin

World Journal of Gastroenterology

Volumn 20, Issue 25, 2014, Pages 8229-8236

  Zhang, Ya Jie ^a   Li, A Jian ^a   Han, Yi ^a   Yin, Lu ^a   Lin, Mou Bin ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Chemosensitivity; Colorectal cancer; Girdin; Oxaliplatin; TOP2B

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GIRDIN; MESSENGER RNA; OXALIPLATIN; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ANTINEOPLASTIC AGENT; CCDC88A PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II BETA; GYRASE INHIBITOR; PLATINUM COMPLEX; VESICULAR TRANSPORT PROTEIN;

ARTICLE; CANCER INHIBITION; CELL DEATH; CHEMOSENSITIVITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LENTIVIRUS INFECTION; MTT ASSAY; PLASMID; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CACO 2 CELL LINE; CELL PROLIFERATION; COLORECTAL TUMOR; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; CELL VIABILITY; GENE EXPRESSION PROFILING; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEQUENCE ANALYSIS; SPECTROPHOTOMETRY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; CELL DEATH; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICROFILAMENT PROTEINS; ORGANOPLATINUM COMPOUNDS; RNA INTERFERENCE; RNA, MESSENGER; TOPOISOMERASE II INHIBITORS; TRANSFECTION; VESICULAR TRANSPORT PROTEINS;

EID: 84903974211     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i25.8229     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078]
2. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351 [PMID: 15175436 DOI: 10.1056/NEJMoa032709]
3. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069 [PMID: 12775730 DOI: 10.1200/JCO.2003.11.126]
4. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 3224-3229 [PMID: 17664470 DOI: 10.1200/JCO.2006.10.4380]
5. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584 [PMID: 17625587 DOI: 10.1038/nrc2167]
6. Huang WC, Hung MC. Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009; 108: 180-194 [PMID: 19293033 DOI: 10.1016/ S0929-6646(09)60051-6]
7. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 2004; 12: 955-965 [PMID: 15492778]
8. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 2012; 1271: 58-67 [PMID: 23050965 DOI: 10.1111/j.1749-6632.2012.06734.x]
9. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3Kdependent and FAK-independent fashion. World J Surg Oncol 2011; 9: 46 [PMID: 21539750 DOI: 10.1186/1477-7819-9-46]
10. Yoon H, Min JK, Lee JW, Kim DG, Hong HJ. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun 2011; 405: 333-337 [PMID: 21130731 DOI: 10.1016/j.bbrc.2010.11.130]
11. Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, Fulda S, Neoptolemos J, Greenhalf W, Barth P, Gress TM, Michl P. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 2010; 59: 1101-1110 [PMID: 20442202 DOI: 10.1136/gut.2009.189720]
12. Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL, Chung YC. Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 2011; 37: 140-147 [PMID: 21194879 DOI: 10.1016/j.ejso.2010.12.003]
13. Dunkel Y, Ong A, Notani D, Mittal Y, Lam M, Mi X, Ghosh P. STAT3 protein up-regulates Gα-interacting vesicleassociated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. J Biol Chem 2012; 287: 41667-41683 [PMID: 23066027 DOI: 10.1074/jbc. M112.390781]
14. Garcia-Marcos M, Kietrsunthorn PS, Pavlova Y, Adia MA, Ghosh P, Farquhar MG. Functional characterization of the guanine nucleotide exchange factor (GEF) motif of GIV protein reveals a threshold effect in signaling. Proc Natl Acad Sci USA 2012; 109: 1961-1966 [PMID: 22308453 DOI: 10.1073/ pnas.1120538109]
15. Matsushita E, Asai N, Enomoto A, Kawamoto Y, Kato T, Mii S, Maeda K, Shibata R, Hattori S, Hagikura M, Takahashi K, Sokabe M, Murakumo Y, Murohara T, Takahashi M. Protective role of Gipie, a Girdin family protein, in endoplasmic reticulum stress responses in endothelial cells. Mol Biol Cell 2011; 22: 736-747 [PMID: 21289099 DOI: 10.1091/mbc. E10-08-0724]
16. Jun BY, Kim SW, Jung CK, Cho YK, Lee IS, Choi MG, Choi KY, Oh ST. Expression of girdin in human colorectal cancer and its association with tumor progression. Dis Colon Rectum 2013; 56: 51-57 [PMID: 23222280 DOI: 10.1097/ DCR.0b013e31826b9b7e]
17. Mao JZ, Jiang P, Cui SP, Ren YL, Zhao J, Yin XH, Enomoto A, Liu HJ, Hou L, Takahashi M, Zhang B. Girdin locates in centrosome and midbody and plays an important role in cell division. Cancer Sci 2012; 103: 1780-1787 [PMID: 22755556 DOI: 10.1111/j.1349-7006.2012.02378.x]
18. Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002; 19: 261-265 [PMID: 12512920]
19. Zhang A, Lyu YL, Lin CP, Zhou N, Azarova AM, Wood LM, Liu LF. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem 2006; 281: 35997-36003 [PMID: 16973621 DOI: 10.1074/jbc.M604149200]
20. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23 [PMID: 17084534 DOI: 10.1016/ j.ctrv.2006.09.006]
21. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495 [PMID: 10688869]
22. Garcia-Marcos M, Ghosh P, Farquhar MG. GIV is a nonreceptor GEF for G alpha i with a unique motif that regulates Akt signaling. Proc Natl Acad Sci USA 2009; 106: 3178-3183 [PMID: 19211784 DOI: 10.1073/pnas.0900294106]
23. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 1993; 53: 5663-5668 [PMID: 8242621]
24. Gupta KP, Swain U, Rao KS, Kondapi AK. Topoisomerase IIβ regulates base excision repair capacity of neurons. Mech Ageing Dev 2012; 133: 203-213 [PMID: 22433436 DOI: 10.1016/j.mad.2012.03.010]
25. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive-and drug-resistant tumor cells. Cell Death Differ 1999; 6: 471-480 [PMID: 10381639 DOI: 10.1038/ sj.cdd.4400512]
26. Gamen S, Anel A, Lasierra P, Alava MA, Martinez-Lorenzo MJ, Piñeiro A, Naval J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a Fas-independent way. FEBS Lett 1997; 417: 360-364 [PMID: 9409752]